Evaluation of a new, fully automated immunoassay for detection of HTLV-I and HTLV-II antibodies

Journal of Medical Virology

Volumn 80, Issue 3, 2008, Pages 484-493

  Qiu, Xiaoxing ^a   Hodges, Steven ^a   Lukaszewska, Teresa ^a   Hino, Shigeo ^b   Arai, Hiroyasu ^c   Yamaguchi, Julie ^a   Swanson, Priscilla ^a   Schochetman, Gerald ^a   Devare, Sushil G ^a  

^a ABBOTT DIAGNOSTICS   (United States)

^b TOTTORI UNIVERSITY   (Japan)

^c Abbott Japan Co Ltd   (Japan)

Author keywords

Blood donor screening; HTLV I; HTLV II; Recombinant antigen; Serological assay

Indexed keywords

RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE;

ANTIBODY DETECTION; ARTICLE; AUTOMATION; BLOOD DONOR; DIAGNOSTIC VALUE; EVALUATION; HOSPITAL PATIENT; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IMMUNOASSAY; JAPAN; NICARAGUA; NONHUMAN; PREGNANT WOMAN; RETROVIRUS; SCREENING; SENSITIVITY AND SPECIFICITY; UNITED STATES; VIRUS INFECTION;

AUTOMATION; BLOOD DONORS; HTLV-I ANTIBODIES; HTLV-I INFECTIONS; HTLV-II ANTIBODIES; HTLV-II INFECTIONS; HUMANS; IMMUNOASSAY; SENSITIVITY AND SPECIFICITY;

HUMAN T-LYMPHOTROPIC VIRUS 1; MUREX;

EID: 38849180114     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21083     Document Type: Article

References (49)

1. Alarcón JO, Friedman HB, Montano SM, Zunt JR, Holmes KK, Quinnan GV. 2006. High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in Peru. J Acquir Immune Defic Syndr 42:604-609.
2. Andersson S, Thorstensson R, Ramirez KG, Krook A, von Sydow M, Dias F, Biberfeld G. 1999. Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa. Transfusion 39:845-851.
3. Andersson S, Gessain A, Taylor GP. 2001. Pooling of samples for seroepidemiological surveillance of human T-cell lymphotropic virus types I and II. Virus Res 78:101-106.
4. Araujo A, Hall WW. 2004. Human T-lymphotropic virus type II and neurological disease. Ann Neurol 56:10-19.
5. Blattner WA, Takatsuki K, Gallo RC. 1983. Human T-cell lukemia-lymphoma virus and adult T-cell leukemia. JAMA 250:1074-1080.
6. Burgisser P, Simon F, Wernli M, Wust T, Beya MF, Frei PC. 1996. Multicenter evaluation of new double-antigen sandwich enzyme immunoassay for measurement of anti-human immunodeficiency virus type 1 and type 2 antibodies. J Clin Microbiol 34:634-637.
7. Calattini S, Chevalier SA, Duprez R, Afonso P, Froment A, Gessain A, Mahieux R. 2006. Human T-cell lymphotropic virus type 3: Complete nucleotide sequence and characterization of the human tax3 protein. J Virol 80:9876-9888.
8. Crofts N, Maskill W, Gust ID. 1988. Evaluation of enzyme-linked immunosorbent assays: A method of data analysis. J Virol Methods 22:51-59.
9. Dodd RY, Notari EP, Stramer SL. 2002. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42:975-979.
10. Gallarda JL, Henrard DR, Liu D, Harrington S, Stramer SL, Valinsky JE, Wu P. 1992. Early detection of antibody to human immunodeficiency virus type 1 by using an antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody. J Clin Microbiol 30:2379-2384.
11. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de Thé G. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2:407-410.
12. Gessain A, Mauclère P, Froment A, Biglione M, Le Hesran JY, Tekaia F, Millan J, de The G. 1995. Isolation and molecular characterization of a human T-cell lymphotropic virus type II (HTLV-II), subtype B, from a healthy Pygmy living in a remote area of Cameroon: An ancient origin of HTLV-II in Africa. Proc Natl Acad Sci USA 92:4041-4045.
13. Hadlock KG, Goh CJ, Bradshaw PA, Perkins S, Lo J, Kaplan JE, Khabbaz R, Foung SK. 1995. Delineation of an immunodominant and human T-cell lymphotropic virus (HTLV)-specific epitope within the HTLV-I transmembrane glycoprotein. Blood 86:1392-1399.
14. Hall WW, Ishak R, Zhu SW, Novoa P, Eiraku N, Takahashi H, Ferreira M, da C, Azevedo V, Ishak MO, Ferreira O, Monken C, Kurata T. 1996. Human T-lymphotropic virus type II (HTLV-II): Epidemiology, molecular properties and clincial features of infection. J Acquir Immune Defic Syndr Hum Retrovir 13:S204-S214.
15. Hartley TM, Malone GE, Khabbaz RF, Lal RB, Kaplan JE. 1991. Evaluation of a recombinant human T-cell lymphotropic virus type I (HTLV-I) p21E antibody detection enzyme immunoassay as a supplementary test in HTLV-I/II antibody testing algorithms. J Clin Microbiol 29:1125-1127.
16. Hino S, Yamaguchi K, Katamine S, Sugiyama H, Amagasaki T, Kinoshita K, Yoshida Y, Doi H, Tsuji Y, Miyamoto T. 1985. Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn J Cancer Res 76:474-480.
17. Hino S, Katamine S, Kawase K, Miyamoto T, Doi H, Tsuji Y, Yamabe T. 1994. Intervention of maternal transmission of HTLV-1 in Nagasaki, Japan. Leukemia 8:S68-S71.
18. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I. 1981. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78:6476-6480.
19. Hjelle B, Appenzeller O, Mills R, Alexander S, Torrez-Martinez N, Jahnke R, Ross G. 1992. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 339:645-646.
20. Horal P, Hall WW, Svennerholm B, Lycke J, Jeansson S, Rymo L, Kaplan MH, Vahlne A. 1991. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc Natl Acad Sci USA 88:5754-5758.
21. Inaba S, Okochi K, Sato H, Fukada K, Kinukawa N, Nakata H, Kinjyo K, Fujii F, Maeda Y. 1999. Efficacy of donor screening for HTLV-I and the natural history of transfusion-transmitted infection. Transfusion 39:1104-1110.
22. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. 1982. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 218:571-573.
23. Kobe B, Center RJ, Kemp BE, Poumbourios P. 1999. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci USA 96:4319-4324.
24. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. 1990. Infective dermatitis of Jamaican children: A marker for HTLV-I infection. Lancet 336:1345-1347.
25. Lal RB, Brodine S, Kazura J, Mbidde-Katonga E, Yanagihara R, Roberts C. 1992. Sensitivity and specificity of a recombinant transmembrane glycoprotein (rgp21)-spiked Western immunoblot for serological confirmation of human T-cell lymphotropic virus type I and type II infections. J Clin Microbiol 30:296-299.
26. Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, Chen IS. 1989. High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science 244:471-475.
27. Lee HH, Swanson P, Rosenblatt JD, Chen IS, Sherwood WC, Smith DE, Tegtmeier GE, Fernando LP, Fang CT, Osame M, Kleinman SH. 1991. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet 337:1435-1439.
28. Ly TD, Martin L, Daghfal D, Sandridge A, West D, Bristow R, Chalouas L, Qiu X, Lou SC, Hunt JC, Schochetman G, Devare SG. 2001. Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: Evaluation of HIV seroconversion sensitivity and subtype detection. J Clin Microbiol 39:3122-3128.
29. Manns A, HisadaM, La Grenade L. 1999. Human T-lymphotropic virus type I infection. Lancet 353:1951-1958.
30. Maskill WJ, Crofts N, Waldman E, Healey DS, Howard TS, Silvester C, Gust ID. 1988. An evaluation of competitive and second generation ELISA screening tests for antibody to HIV. J Virol Methods 22:61-73.
31. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K, Hinuma Y. 1981. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 294:770-771.
32. Morgan OS, Rodgers-Johnson P, Mora C, Char G. 1989. HTLV-1 and polymyositis in Jamaica. Lancet 2:1184-1187.
33. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. 1989. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 333:441.
34. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M. 1986. HTLV-I associated myelopathy: A new clinical entity. Lancet 1:1031-1032.
35. Palker TJ, Tanner ME, Scearce RM, Streilein RD, Clark ME, Haynes BF. 1989. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. J Immunol 142:971-978.
36. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77:7415-7419.
37. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. 2005. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24:6058-6068.
38. Rodgers-Johnson P, Gajdusek DC, Morgan OS, Zaninovic V, Sarin PS, Graham DS. 1985. HTLV-I and HTLV-III antibodies and tropical spastic paraparesis. Lancet 2:1247-1248.
39. Shah DO, Chang CD, Jiang LX, Cheng KY, Muerhoff AS, Guttierrez RA, Leary TP, Desai SM, Batac-Herman IV, Salbilla VA, Haller AS, Stewart JL, Dawson GJ. 2003. Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzer. Transfusion 43:1067-1074.
40. Sickinger E, Stieler M, Kaufman B, Kapprell HP, West D, Sandridge A, Deware S, Schochetman G, Hunt JC, Daghtal D, AX SYM Clinical Study Group. 2004. Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J Clin Microbiol 142:21-29.
41. Switzer WM, Qari SH, Wolfe ND, Burke DS, Folks TM, Heneine W. 2006. Ancient origin and molecular features of the novel human T-lymphotropic virus type 3 revealed by complete genome analysis. J Virol 80:7427-7438.
42. Taylor GP, Bodéus M, Courtois F, Pauli G, Del Mistro A, Machuca A, Padua E, Andersson S, Goubau P, Chieco-Bianchi L, Soriano V, Coste J, Ades AE, Weber JN. 2005. The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: A prospective study of pregnant women. J Acquir Immune Defic Syndr 38:104-109.
43. Varma M, Rudolph DL, Knuchel M, Switzer WM, Hadlock KG, Velligan M, Chan L, Foung SK, Lal RB. 1995. Enhanced specificity of truncated transmembrane protein for serologic confirmation of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infections by Western blot (immunoblot) assay containing recombinant envelope glycoproteins. J Clin Microbiol 33:3239-3244.
44. Vrielink H, Reesink HW, Habibuw MR, Schuller M, van der Meer CBM, Lelie PN. 1999. Comparison of four HTLV-I and HTLV-I + II ELISAs. Vox Sang 76:187-191.
45. Watanabe T, Mochizuki M, Yamaguchi K. 1997. HTLV-1 Uveitis (HU). Leukemia 11:582-584.
46. Yakova M, Lézin A, Dantin F, Lagathu G, Olindo S, Jean-Baptiste G, Arfi S, Césaire R. 2005. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2:4-12.
47. Yamada K, Kuroda N, Washitani Y, Shiraki H, Maeda Y. 1992. Enzyme immunoassay with synthetic peptides to detect anti-HTLV-I antibodies. Clin Chem 38:699-703.
48. Yamaguchi K, Seiki M, Yoshida M, Nishimura H, Kawano F, Takatsuki K. 1984. The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy. Blood 63:1235-1240.
49. Yoshida M, Miyoshi I, Hinuma Y. 1982. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. PNAS 79:2031-2035.